Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02418104 · ClinicalTrials.gov registry record · Phase 1
Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®
A Phase 1 study, sponsored by Coherus Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 303
- Enrollment target
NCT02418104: Completed Phase 1 study, sponsored by Coherus Oncology.
NCT02418104 is a Phase 1 study that has completed, run by Coherus Oncology. The registered enrollment target is 303 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (405% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02418104, a Phase 1 study, has completed, sponsored by Coherus Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 303 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, 2-period parallel study in healthy subjects to assess immunogenicity and safety of two sequential 6 mg subcutaneous (SC) injections of CHS-1701 compared with two sequential 6 mg SC injections of Neulasta®.
Primary Outcome
The primary objective of this study is to assess the immunogenicity of CHS-1701 compared to Neulasta based on the development of neutralizing antibodies (NAB) and the percent difference in ADA response
Interventions
- DRUG CHS-1701
- DRUG Pegfilgrastim (Neulasta)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 303 participants |
| Start Date | 2015-05 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
What the finished NCT02418104 record still lists
NCT02418104 is an interventional study that assigns participants to a tested intervention. The registered 303 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (405% higher).
The record links to 0 conditions, and to 2 interventions - of which CHS-1701 is the first listed.
NCT02418104 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02418104 about?
NCT02418104 is a clinical study titled "Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®". This is a randomized, double-blind, 2-period parallel study in healthy subjects to assess immunogenicity and safety of two sequential 6 mg subcutaneous (SC) injections of CHS-1701 compared with two sequential 6 mg SC injections of Neulasta®.
What is the current status of trial NCT02418104?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 303 participants. The study started on 2015-05. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02418104?
The interventions under investigation include: CHS-1701 (DRUG), Pegfilgrastim (Neulasta) (DRUG).
Who is sponsoring clinical trial NCT02418104?
This trial is sponsored by Coherus Oncology, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02418104's enrollment target sits among peer trials
303 124th of 2000 higher than 1,877 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05508971 · 303 participants · NA
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)
- NCT04750616 · 304 participants · Phase 2
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
- NCT04994717 · 304 participants · Phase 3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
- NCT06036147 · 304 participants · NA
Concussion Health Improvement Program
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia